IDEXX Laboratories Files 8-K Report
Ticker: IDXX · Form: 8-K · Filed: Dec 9, 2024 · CIK: 874716
| Field | Detail |
|---|---|
| Company | Idexx Laboratories Inc /De (IDXX) |
| Form Type | 8-K |
| Filed Date | Dec 9, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.10 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, regulatory-update
Related Tickers: IDXX
TL;DR
IDXX filed an 8-K, likely containing routine disclosures or exhibit updates.
AI Summary
On December 3, 2024, IDEXX Laboratories, Inc. filed an 8-K report to disclose other events and financial statements/exhibits. The filing does not contain specific financial figures or details about the 'other events' beyond its classification.
Why It Matters
This 8-K filing indicates that IDEXX Laboratories has made a regulatory submission to the SEC, which may contain important updates or disclosures for investors.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for 'Other Events' and 'Financial Statements and Exhibits' without immediate, specific financial impacts disclosed.
Key Players & Entities
- IDEXX LABORATORIES INC /DE (company) — Registrant
- December 3, 2024 (date) — Date of earliest event reported
- Westbrook, Maine (location) — Principal executive offices location
FAQ
What specific 'Other Events' are being reported by IDEXX Laboratories in this 8-K filing?
The filing categorizes the event as 'Other Events' but does not provide specific details about the nature of these events within the provided text.
What is the significance of filing 'Financial Statements and Exhibits' in this 8-K?
This indicates that the company is providing updated financial statements or exhibits as required by the SEC, though the content of these is not detailed in the provided excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported is dated December 3, 2024.
Where are IDEXX Laboratories' principal executive offices located?
The principal executive offices of IDEXX Laboratories are located at One IDEXX Drive, Westbrook, Maine 04092.
What is the SEC file number for IDEXX Laboratories?
The SEC file number for IDEXX Laboratories is 000-19271.
Filing Stats: 564 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2024-12-09 07:32:51
Key Financial Figures
- $0.10 — ange on which registered Common Stock, $0.10 par value per share IDXX NASDAQ Global
Filing Documents
- idxx-20241203.htm (8-K) — 29KB
- ex991-idxxsharerepurchase.htm (EX-99.1) — 7KB
- idexxlogo.jpg (GRAPHIC) — 30KB
- idxx-20241203_g1.jpg (GRAPHIC) — 47KB
- 0000874716-24-000148.txt ( ) — 338KB
- idxx-20241203.xsd (EX-101.SCH) — 2KB
- idxx-20241203_def.xml (EX-101.DEF) — 15KB
- idxx-20241203_lab.xml (EX-101.LAB) — 26KB
- idxx-20241203_pre.xml (EX-101.PRE) — 15KB
- idxx-20241203_htm.xml (XML) — 3KB
01. Other Events
Item 8.01. Other Events. On December 3, 2024, the Finance Committee of the Board of Directors (the "Board") of IDEXX Laboratories, Inc. (the "Company") authorized an increase in the Company's ongoing share repurchase program, authorizing the repurchase of up to five million additional shares of the Company's common stock. Repurchases may be made at management's discretion from time to time in the open market (including through Rule 10b5-1 plans) or in negotiated transactions. These shares are in addition to the 1.3 million shares remaining under the Company's ongoing share repurchase program as of December 3, 2024, pursuant to previous Board authorizations. The share repurchase program has no specified expiration date and may be suspended or discontinued at any time. The increase in the number of shares authorized under the share repurchase program is described in a press release issued by the Company on December 9, 2024, which is attached hereto as Exhibit 99.1.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits 99.1 Press Release entitled "IDEXX Laboratories Announces Increase in Share Repurchase Program Authorization" issued by the Company on December 9, 2024 . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IDEXX LABORATORIES, INC. Date: December 9, 2024 By: /s/ Sharon E. Underberg Sharon E. Underberg Executive Vice President, General Counsel and Corporate Secretary